← Back to patent-cliff list
Tivanisiran
Tier C — Watch / tradeTivanisiran
Sylentis Sa
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Nucleic acid drug
Type
Targets：TRPV1
Indications (approved)：Sjogren-Larsson综合征, Dry eye syndrome, 眼睛疼痛, Dry eye disease
Regional status
US
Phase III
2021-05-25
EU
Phase III
2017-05-18
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Tivanisiran?
Approved indications include: Sjogren-Larsson综合征, Dry eye syndrome, 眼睛疼痛, Dry eye disease.
When does the Tivanisiran patent expire?
No public expiry year is available for Tivanisiran yet; this page updates once verified.
How do I get a quote for Tivanisiran intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-09